ClinicalTrials.gg
CompletedNCT00237133PREDICTUpdated Feb 24, 2017

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

A Phase 4 interventional study of Letrozole in Locally Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
74th of 159
112 · median 95
Started
2003
with 6 others
Phase 4
17 of 162
2 open now
Registered
18th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 74th largest by enrollment of the 159 interventional ones that give a count, is one of 7 that started in 2003, is one of 17 in phase 4, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)

03

Conditions studied

  • Locally Advanced Breast Cancer

Browse trials for

Keywords

  • Breast cancer,
  • Letrozole,
  • Hormonal receptors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women
  2. Primary locally invasive breast cancer
  3. Histological confirmed by core needle , whose tumors are estrogen (ER) and / or progesterone (PgR) positive, defined by core biopsy immunohistochemistry with > 10% positive malignant epithelial cells.
  4. Post menopausal status
  5. Tumor measurable by clinical examination, mammography and ultrasound

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with letrozole or tamoxifen.
  2. Patients with bilateral breast tumors
  3. Patients who are eligible for breast conserving surgery
  4. Evidence of inflammatory breast cancer or distant .
  5. Other concurrent malignant disease
  6. Concomitant anti-cancer treatments such as chemotherapy

Other protocol-defined exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Letrozole

    Drug: Letrozole

Interventions

  • 1 tablet of Letrozole 2.5 mg orally adminnistered once a day

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of Letrozole

    Time frame: frequency and severity of the clinical adverse events

07

Study locations

11 sites
  • Novartis Investigative Site
    Barretos - SP, Brazil
  • Novartis Investigative Site
    Florianopolis - SC, Brazil
  • Novartis Investigative Site
    Fortaleza/CE, Brazil
  • Novartis Investigative Site
    Goiania/GO, Brazil
  • Novartis Investigative Site
    Jau -SP, Brazil
  • Novartis Investigative Site
    Porto Alegre/RS, Brazil
  • Novartis Investigative Site
    Ribeirao - SP, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, Brazil
  • Novartis Investigative Site
    Santo Andre, Brazil
  • Novartis Investigative Site
    Sao Paulo/SP, Brazil
  • Novartis Investigative Site
    Vitoria/ES, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2005
First posted
Oct 12, 2005
Start
Mar 2003
Primary completionActual
Jan 2009
CompletionActual
Jan 21, 2009
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00237133
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Mar 2003
Primary completion
Jan 2009
Completion
Jan 21, 2009
Last update
Feb 24, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion